The value of waste

This paper argues that a first step in finding a sustainable solution for the pressing global issue of ‘waste’, is to consider waste a value attribution rather than a material condition. Doing so means a shift in focus from finding more efficient ways to ‘clean up the mess’ to changing the way in which value is attributed to things. The paper looks at a selection of recent literature on value systems to identify useful concepts and theory for a value-based solution to waste. Furthermore, art and design are proposed to explore and probe such potential solutions

New aesthetic, new anxieties

The New Aesthetic was a design concept and netculture phenomenon launched into the world by London designer James Bridle in 2011. It continues to attract the attention of media art, and throw up associations to a variety of situated practices, including speculative design, net criticism, hacking, free and open source software development, locative media, sustainable hardware and so on. In this book we consider the New Aesthetic: as an opportunity to rethink the relations between these contexts in the emergent episteme of computationality. There is a desperate need to confront the political pressures of neoliberalism manifested in these infrastructures. Indeed, these are risky, dangerous and problematic times; a period when critique should thrive. But here we need to forge new alliances, invent and discover problems of the common that nevertheless do not eliminate the fundamental differences in this ecology of practices. In this book, perhaps provocatively, we believe a great deal could be learned from the development of the New Aesthetic not only as a mood, but as a topic and fix for collective feeling, that temporarily mobilizes networks. Is it possible to sustain and capture these atmospheres of debate and discussion beyond knee-jerk reactions and opportunistic self-promotion? These are crucial questions that the New Aesthetic invites us to consider, if only to keep a critical network culture in place

Artists and designers as agents of change

This paper will focus on the role of artists and designers as agents of change in sustainability innovation. We will analyse the characteristics of this role on the basis of a review of literature that discusses various concepts, methodologies and strategies applied by artists and designers in innovation processes. The paper will analyse two case studies in which artists and designers acted as agents of change and will discuss insights from these case studies in the light of the literature reviewed. We will then continue to investigate how certain characteristics of the involvement of artists and designers in innovation processes relate to the impact of the process on a social-, business- or product level. The paper will conclude with lessons learnt regarding the role of artists and designers as agents of change in innovation processes and will introduce directions for future research

Medication Use and Clinical Outcomes by the Dutch Institute for Clinical Auditing Medicines Program: Quantitative Analysis

BACKGROUND: The Dutch Institute for Clinical Auditing (DICA) Medicines Program was set up in September 2018 to evaluate expensive medicine use in daily practice in terms of real-world effectiveness using only existing data sources. OBJECTIVE: The aim of this study is to describe the potential of the addition of declaration data to quality registries to provide participating centers with benchmark information about the use of medicines and outcomes among patients. METHODS: A total of 3 national population-based registries were linked to clinical and financial data from the hospital pharmacy, the Dutch diagnosis treatment combinations information system including in-hospital activities, and survival data from health care insurers. The first results of the real-world data (RWD) linkage are presented using descriptive statistics to assess patient, tumor, and treatment characteristics. Time-to-next-treatment (TTNT) and overall survival (OS) were estimated using the Kaplan-Meier method. RESULTS: A total of 21 Dutch hospitals participated in the DICA Medicines Program, which included 7412 patients with colorectal cancer, 1981 patients with metastasized colon cancer, 3860 patients with lung cancer, 1253 patients with metastasized breast cancer, and 7564 patients with rheumatic disease. The data were used for hospital benchmarking to gain insights into medication use in specific patient populations, treatment information, clinical outcomes, and costs. Detailed treatment information (duration and treatment steps) led to insights into differences between hospitals in daily clinical practices. Furthermore, exploratory analyses on clinical outcomes (TTNT and OS) were possible. CONCLUSIONS: The DICA Medicines Program shows that it is possible to gather and link RWD about medicines to 4 disease-specific population-based registries. Since these RWD became available with minimal registration burden and effort for hospitals, this method can be explored in other population-based registries to evaluate real-world efficacy